New rapid blood test could slash unnecessary antibiotic use in sepsis
NCT ID NCT06069206
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a rapid blood test (T2Bacteria Panel) that identifies bacteria directly from blood, compared to standard blood cultures that take 1-3 days. Researchers wanted to see if using this test could help doctors stop unnecessary vancomycin (a strong antibiotic) sooner in 500 adults with suspected sepsis. The goal is to reduce side effects and antibiotic resistance while still treating infections effectively.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- T2Bacteria Panel (direct-from-blood bacterial test)
- What this could lead to
- If successful, this test could help doctors stop unnecessary antibiotics sooner, reducing side effects and antibiotic resistance.
- What could go wrong
- This is a single-center trial with 500 patients, so results may not apply everywhere. The test may not always be accurate, and faster antibiotic changes might not improve overall outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
500 people
The number who actually took part.
- Started
-
Dec 2023
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient is located in the Emergency Department at Vanderbilt University Hospital * ≤ 12 hours from patient presentation to the Emergency Department at Vanderbilt University Hospital * Age ≥ 18 years * Clinician has ordered blood cultures * Clinician has ordered intravenous vancomycin Exclusion Criteria: * Patient is known to be a prisoner * Patient is known to be pregnant * Patient is known to have received 2 or more doses of vancomycin since presentation to the Vanderbilt ED * Patient is known to have a positive bacterial culture in the previous 7 days * Patient is known to have an infection for which at least 7 days of intravenous vancomycin would routinely be administered regardless of bacterial testing results (e.g., skin and soft tissue infection, etc.)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bloodstream infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a computer model speed up sepsis blood tests?
- Can kids with blood infections skip the IV earlier?
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Could one blood draw be enough to catch dangerous infections?
- A 5-hour test may replace days of waiting for the right antibiotic in blood infections
- Scientists hunt for hidden clues to drug reactions in the blood